In a UK Biobank analysis of 416,118 adults, statin users showed 7% lower odds of DNMT3A-mutant clonal hematopoiesis (CH) overall (OR=0.93), with a striking 22% reduction specifically for the high-risk DNMT3AR882 hotspot mutation (OR=0.78). Mendelian randomization further showed that genetically proxied HMG-CoA reductase inhibition equivalent to a 1-SD LDL reduction conferred 34% lower odds of DNMT3A-mutant CH (OR=0.66). No protective signal emerged for TET2-mutant CH. Critically, polygenic LDL-lowering variants showed no association, implying the protective effect is independent of cholesterol reduction and likely reflects direct HMGCR pathway biology in hematopoietic stem cells. In vitro confirmation — pravastatin selectively suppressing DNMT3AR882-mutant colony formation relative to wild-type cells — adds mechanistic weight.
Clonal hematopoiesis, affecting roughly 10–15% of adults over 70, elevates cardiovascular disease and leukemia risk substantially yet has no approved preventive therapy. This finding is potentially paradigm-shifting: it repositions a widely prescribed drug class as a candidate CH preventive agent with a mutation-specific target. However, several cautions apply. The observational arm cannot exclude residual confounding despite multivariable adjustment. The MR instrument for HMGCR is a single variant (rs12916), limiting power. The in vitro work uses cells from a single donor. As an unpeer-reviewed preprint posted on medRxiv, these results require independent replication and formal clinical validation before any prescribing implications can be drawn. Still, the convergence of epidemiological, genetic, and cellular evidence makes this one of the more compelling CH prevention leads to date.
